免疫检查点抑制剂诱发多发性浆膜炎、乳糜腹水和肝炎一例。
A Case of Polyserositis, Chylous Ascites and Hepatitis Induced by Immune Checkpoint Inhibitors.
发表日期：2024
作者：
Marta Castelli, Mauro Betelli, Anna Valenti, Barbara Merelli, Alessandro Loglio, Mauro Viganò, Alberto Benetti
来源：
Immunity & Ageing
摘要：
我们描述了纳武单抗治疗后出现多发性浆膜炎伴乳糜性腹水的罕见病例，强调了识别和管理与免疫检查点抑制剂 (ICPIs) 相关的免疫相关不良事件 (irAE) 的挑战。诱发的多发性浆膜炎和乳糜性腹水非常罕见，需要免疫抑制治疗，高剂量静脉注射类固醇的反应各不相同。免疫检查点抑制剂 (ICPIs) 的肿瘤治疗经常与免疫相关不良事件 (irAE) 相关，大多数涉及皮肤、胃肠道和肺部部位。© EFIM 2024。
We describe a rare case of polyserositis with chylous ascites following nivolumab therapy, highlighting the challenges in recognising and managing immune-related adverse events (irAEs) associated with immune checkpoint inhibitors (ICPIs). Induced polyserositis and chylous ascites are very rare and require immunosuppressive treatment, with a variable response of high-dose IV steroids.Oncological therapy with immune checkpoint inhibitors (ICPIs) is frequently associated with immune-related adverse events (irAEs) most involving cutaneous, gastrointestinal and pulmonary sites.© EFIM 2024.